Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
about
F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profileTAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activityd-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismDopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptorsSynthesis and evaluation of a series of 2-substituted-5-thiopropylpiperazine (piperidine)-1,3,4-oxadiazoles derivatives as atypical antipsychoticsInvestigating the Role of Serotonin in Methamphetamine Psychosis: Unaltered Behavioral Effects of Chronic Methamphetamine in 5-HT1A Knockout Mice.Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia.Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.Effects of haloperidol and clozapine on sensorimotor gating deficits induced by 5-hydroxytryptamine depletion in the brain.Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats.Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.Classics in Chemical Neuroscience: Aripiprazole.Efficacy and tolerability of aripiprazole in patients with schizophrenia & schizoaffective disorders.Autoradiographic evaluation of [3H]CUMI-101, a novel, selective 5-HT1AR ligand in human and baboon brain.G protein-coupled receptors in major psychiatric disorders.Synthesis and evaluation of arylpiperazines derivatives of 3,5-dioxo-(2H,4H)-1,2,4-triazine as 5-HT1AR ligands.The stimulus effects of 8-OH-DPAT: evidence for a 5-HT2A receptor-mediated component.Aripiprazole-induced seizure: a second case report.Tracheal occlusion conditioning in conscious rats modulates gene expression profile of medial thalamus.Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions.5-HT2A receptor antagonist M100907 reduces serotonin synthesis: an autoradiographic studyEffects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.Aripiprazole in the treatment of Huntington's disease: a case series.Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors.Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum.
P2860
Q24564963-B60D2967-79F3-4AE4-B3C7-690C1788B07FQ24564964-529531BC-86D4-4BCF-A5B3-B8B6121C6461Q24631419-C4DFBCB3-BB0D-4B96-A336-64EA3DB182C8Q28067851-FBDAB7B3-FD77-4898-AF65-0D4C0BEBAF09Q28084069-D9187200-B776-49D1-8634-70AA9E71D86FQ28273285-20D50A19-8382-4B62-9FB4-0447A2B3730EQ28483019-B4FF06BB-04F1-4694-83AB-2B4CD13C66F2Q30357167-4D511A3E-1E1D-442F-A8C1-FB6B5A16F8C4Q30445688-9F1EB170-E05D-4B0A-8483-3C7E6A67D153Q30493133-958B5C9C-8B80-4B54-9040-E43BD3073C36Q30494674-61171D6C-1473-4943-98AD-4093147B3700Q30498658-16818DE0-9CEA-41E3-8CD5-7946AD486BFAQ33643175-D8774F6D-21ED-4C78-9BF1-3535A57D2589Q33858314-DBDEFEF1-7CE7-45E6-97FD-793AFB952136Q33866125-4F2DED23-6E07-4423-892D-3FF1D87D654DQ34174978-EB41A728-B630-4068-BE37-027485E45BCDQ34214169-4002DA9D-0430-4A26-BD62-25445BFD85CFQ34578414-D0FF26CE-06CA-45B2-B884-0563B58BDB2FQ34960954-A7E4DA62-14C8-4A85-BDC2-C0478A79A98AQ36569606-B74A4F8F-FCAA-4848-A769-55F1A199DF96Q37900852-0B836935-241A-4934-8816-1E66523B429BQ38501908-0F408528-B992-444C-A4D7-B1051CDBFF9BQ40226041-8DF740DC-D838-4D93-9AF3-A052C099CA13Q40698477-4A061D0D-20D8-4B37-9F83-FBA44994947DQ41449158-C2989CC0-D44C-4D6B-8844-2936C9231218Q41529267-790CC518-B609-444C-8FB7-0D24AFA945F8Q41967962-FBFD98F9-4267-45A7-BD9E-55DCA0614779Q42036250-1BEDFB41-CDB9-4212-83C3-FA40E16C7B49
P2860
Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
@ast
Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
@en
Improving the treatment of schizophrenia: focus on serotonin
@nl
type
label
Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
@ast
Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
@en
Improving the treatment of schizophrenia: focus on serotonin
@nl
prefLabel
Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
@ast
Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
@en
Improving the treatment of schizophrenia: focus on serotonin
@nl
P1476
Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors
@en
P2093
P304
P407
P577
2000-12-01T00:00:00Z